Drug companies swallow Japan’s bitter pill
Swiss pharmaceutical manufacturer Novartis is the latest company to feel the wrath of the Japanese authorities over transfer pricing. The Japanese government has fined Novartis' Japanese subsidiary, Ciba-Geigy Japan, ¥3.3 billion ($28 million) for underreporting its income by ¥8 billion between 1990 and 1994.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
